The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck small research deals.

Fintel reports that on July 23, 2025, BMO Capital downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Underperform. Analyst Price Forecast Suggests 595.73% Upside As of ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for ...

Replimune (REPL) stock rebounds even as FDA rejection of its RP1 skin cancer drug lead to multiple analyst downgrades on Wall Street. Read more here.

"REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% After FDA Response Letter -- BFA Law Announces Securities Fraud Investigation And Urges Investors To Contact The Firm >REPL" was published ...

Replimune said the agency had issued a complete response letter regarding the company’s biologics license application for RP1 ...

The stock may have garnered more headlines due to various legal challenges over the past few years, but it remains an excellent long-term option, especially for income seekers. Here's the rundown.

Bill Gates’ net worth dropped a jaw-dropping $51 billion in just days this month because he’s giving so much money away.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn’t one of them.

Unless the stock plummets ahead of Thursday's update, it will be seven consecutive quarters of Netflix moving higher between quarterly reports. 2. Rattle analysts out of their slumber ...

The DJI Mic 2 is a go-to for content creators, and it is rarely on sale. Take advantage of today's offer, because it will be gone tomorrow!